IL267393B2 - Crystal forms of a Janus kinase inhibitor - Google Patents

Crystal forms of a Janus kinase inhibitor

Info

Publication number
IL267393B2
IL267393B2 IL267393A IL26739319A IL267393B2 IL 267393 B2 IL267393 B2 IL 267393B2 IL 267393 A IL267393 A IL 267393A IL 26739319 A IL26739319 A IL 26739319A IL 267393 B2 IL267393 B2 IL 267393B2
Authority
IL
Israel
Prior art keywords
crystalline
composition
item
added
peak
Prior art date
Application number
IL267393A
Other languages
English (en)
Hebrew (he)
Other versions
IL267393A (en
IL267393B1 (en
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of IL267393A publication Critical patent/IL267393A/en
Publication of IL267393B1 publication Critical patent/IL267393B1/en
Publication of IL267393B2 publication Critical patent/IL267393B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL267393A 2016-12-21 2019-06-16 Crystal forms of a Janus kinase inhibitor IL267393B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Publications (3)

Publication Number Publication Date
IL267393A IL267393A (en) 2019-08-29
IL267393B1 IL267393B1 (en) 2023-03-01
IL267393B2 true IL267393B2 (en) 2023-07-01

Family

ID=60991475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267393A IL267393B2 (en) 2016-12-21 2019-06-16 Crystal forms of a Janus kinase inhibitor

Country Status (13)

Country Link
US (1) US11339181B2 (enExample)
EP (1) EP3559003B1 (enExample)
JP (3) JP2020502224A (enExample)
KR (1) KR102788829B1 (enExample)
CN (2) CN110325536A (enExample)
AU (1) AU2017380213B2 (enExample)
BR (1) BR112019012210A2 (enExample)
CA (1) CA3044771A1 (enExample)
ES (1) ES2926986T3 (enExample)
IL (1) IL267393B2 (enExample)
MX (1) MX386181B (enExample)
TW (1) TWI822666B (enExample)
WO (1) WO2018117153A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
JP7597714B2 (ja) * 2019-08-07 2024-12-10 ロート製薬株式会社 涙液分泌促進用眼科組成物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
AU2024229918A1 (en) * 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500666A (ja) * 2005-07-07 2009-01-08 トムソン ライセンシング 対応スタンドを備えたフラット画面ディスプレイシステム
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
BRPI1012108B8 (pt) * 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R ED - MONTCHAMP JEAN-LUC,, CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS, 31 December 1998 (1998-12-31) *

Also Published As

Publication number Publication date
CN121045220A (zh) 2025-12-02
US20200017527A1 (en) 2020-01-16
BR112019012210A2 (pt) 2019-11-12
KR20190092440A (ko) 2019-08-07
CN110325536A (zh) 2019-10-11
JP2023024729A (ja) 2023-02-16
MX2019007462A (es) 2019-08-29
EP3559003B1 (en) 2022-08-24
JP2024161449A (ja) 2024-11-19
AU2017380213B2 (en) 2022-01-06
RU2019122566A3 (enExample) 2021-12-22
MX386181B (es) 2025-03-18
US11339181B2 (en) 2022-05-24
TW201829423A (zh) 2018-08-16
WO2018117153A1 (en) 2018-06-28
EP3559003A1 (en) 2019-10-30
JP2020502224A (ja) 2020-01-23
IL267393A (en) 2019-08-29
ES2926986T3 (es) 2022-10-31
IL267393B1 (en) 2023-03-01
AU2017380213A1 (en) 2019-05-23
TWI822666B (zh) 2023-11-21
RU2019122566A (ru) 2021-01-22
CA3044771A1 (en) 2018-06-28
KR102788829B1 (ko) 2025-03-31

Similar Documents

Publication Publication Date Title
AU2017380213B2 (en) Crystalline forms of a janus kinase inhibitor
JP2023508482A (ja) スピロ環含有キナゾリン化合物
WO2022237843A1 (zh) Axl抑制剂
EP4332102A1 (en) Isoquinolone compound and use thereof
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
KR20200096261A (ko) 설폰아마이드 화합물 및 이의 용도
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
US9862687B2 (en) Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
AU2019378907A1 (en) A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin
CN111655694A (zh) 吡唑并[1，5-a]嘧啶化合物的盐及其晶体
CN112313233A (zh) Jak家族激酶的小分子抑制剂
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
JP2018127429A (ja) インドール酢酸アミド誘導体
EP4692089A1 (en) Nitrogen-containing heterocyclic compound as aak1 inhibitor
EP2975035B1 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
CN117659049A (zh) 取代桥环类抑制剂及其制备方法和应用
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
CN112543634A (zh) Ebna1抑制剂晶体形式及其制备和使用方法
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição
WO2026037254A1 (zh) 作为mrgprx2拮抗剂的化合物
US20230034132A1 (en) Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof
CA3288200A1 (en) Nitrogen-containing heterocyclic compound as aak1 inhibitor
US20060281690A1 (en) Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses
CN119798232A (zh) N-甲酰胺基吡唑啉化合物的晶型及其制备方法和应用
CN116437917A (zh) Atx抑制剂氘代衍生物及其应用